Directors of Pfizer could decide as early as today on a successor to Hank McKinnell, the chairman and chief executive, possibly ending a fierce competition within the company, a person close to Pfizer said last night.
Directors could also decide to hasten Mr. McKinnell's retirement, which is now scheduled to take place in February 2008, when he will reach Pfizer's mandatory retirement age of 65, this person said.
Hat tip: FT
In February 2005, Pfizer appointed three executives to the position of vice chairman, in what was widely seen as setting up a horse race to succeed McKinnell.
Those three are: David Shedlarz, Pfizer's former chief financial officer, who oversees finance and strategic planning; Karen Katen, who oversees the company's pharmaceutical operations; and Jeff Kindler, who oversees legal and corporate affairs.
Although clearly capable of doing the job, Dr Peter Rost is now viewed as a rank outsider! His excellent new blog is taking up too much time, Insider understands.
No comments:
Post a Comment